Home / Compare / Orforglipron vs Semaglutide

Orforglipron vs Semaglutide

Orforglipron vs Semaglutide: how they work, doses used, FDA status and trial weight loss (about 12% vs 14.9%), with sources.

OrforglipronSemaglutide
Works onGLP-1 only (small molecule, not a peptide)GLP-1 only
How it is takenTablet, once daily (Foundayo)Injection weekly (Ozempic, Wegovy) or daily tablet
US statusFDA-approved April 2026 (weight)FDA-approved (2017 diabetes, 2021 weight)
Highest dose17.2 mg daily (label)2.4 mg weekly, or 7.2 mg (Wegovy HD, 2026)
Key trialATTAIN-1 (phase 3)STEP 1 (phase 3)
Average weight lossabout 12% at 72 weeks (highest dose)14.9% at 68 weeks (2.4 mg weekly)
Placebo in that trialabout 1-2%2.4%
Not a head-to-head comparison. The weight-loss numbers come from separate trials with different people, doses and lengths. A direct trial is the only way to know which works better.

How they differ

Orforglipron works on glp-1 only (small molecule, not a peptide); Semaglutide works on glp-1 only. Orforglipron is taken as: tablet, once daily (foundayo).Semaglutide is taken as: injection weekly (ozempic, wegovy) or daily tablet.

Dose schedules and warnings: Orforglipron dosage chart ยท Semaglutide dosage chart.

Questions

Is orforglipron stronger than semaglutide?
No trial has compared them directly. In separate trials, Orforglipron averaged about 12% weight loss (ATTAIN-1 (phase 3), 72 weeks) and Semaglutide 14.9% (STEP 1 (phase 3), 68 weeks). Different trials enroll different people over different lengths of time, so the numbers are not a fair head-to-head comparison.
Is orforglipron FDA-approved?
FDA-approved April 2026 (weight).
Is semaglutide FDA-approved?
FDA-approved (2017 diabetes, 2021 weight).

Sources

  1. Healio: FDA approves orforglipron, an oral GLP-1, for adults with obesity (Apr 2026)
  2. Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021

Last checked 2026-11-16. How we pick and check sources: methodology.